vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and James River Group Holdings, Inc. (JRVR). Click either name above to swap in a different company.
James River Group Holdings, Inc. is the larger business by last-quarter revenue ($167.7M vs $86.8M, roughly 1.9× IOVANCE BIOTHERAPEUTICS, INC.). On growth, James River Group Holdings, Inc. posted the faster year-over-year revenue change (32.4% vs 17.7%). James River Group Holdings, Inc. produced more free cash flow last quarter ($-23.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -8.7%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
James River Corporation was an American pulp and paper company based in Richmond, Virginia, once the largest paper manufacturer in the world.
IOVA vs JRVR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $167.7M |
| Net Profit | — | $32.1M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | 14.6% |
| Net Margin | — | 19.1% |
| Revenue YoY | 17.7% | 32.4% |
| Net Profit YoY | — | 149.5% |
| EPS (diluted) | — | $0.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $167.7M | ||
| Q3 25 | $67.5M | $172.7M | ||
| Q2 25 | $60.0M | $174.8M | ||
| Q1 25 | $49.3M | $172.3M | ||
| Q4 24 | $73.7M | $126.7M | ||
| Q3 24 | $58.6M | $191.5M | ||
| Q2 24 | $31.1M | $188.3M | ||
| Q1 24 | $715.0K | $201.1M |
| Q4 25 | — | $32.1M | ||
| Q3 25 | $-91.3M | $1.0M | ||
| Q2 25 | $-111.7M | $4.8M | ||
| Q1 25 | $-116.2M | $9.6M | ||
| Q4 24 | — | $-64.8M | ||
| Q3 24 | $-83.5M | $-39.4M | ||
| Q2 24 | $-97.1M | $7.6M | ||
| Q1 24 | $-113.0M | $15.4M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | 14.6% | ||
| Q3 25 | -140.7% | 1.5% | ||
| Q2 25 | -189.8% | 4.2% | ||
| Q1 25 | -245.8% | 9.3% | ||
| Q4 24 | -117.5% | -57.0% | ||
| Q3 24 | -152.1% | -27.1% | ||
| Q2 24 | -327.6% | 10.7% | ||
| Q1 24 | -16464.6% | 16.4% |
| Q4 25 | — | 19.1% | ||
| Q3 25 | -135.3% | 0.6% | ||
| Q2 25 | -186.2% | 2.7% | ||
| Q1 25 | -235.5% | 5.6% | ||
| Q4 24 | — | -51.1% | ||
| Q3 24 | -142.7% | -20.6% | ||
| Q2 24 | -312.2% | 4.0% | ||
| Q1 24 | -15800.8% | 7.7% |
| Q4 25 | — | $0.59 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | $-0.33 | $0.06 | ||
| Q1 25 | $-0.36 | $0.16 | ||
| Q4 24 | $-0.24 | $-2.44 | ||
| Q3 24 | $-0.28 | $-1.10 | ||
| Q2 24 | $-0.34 | $0.13 | ||
| Q1 24 | $-0.42 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $260.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $538.2M |
| Total Assets | $913.2M | $4.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $260.9M | ||
| Q3 25 | $300.8M | $238.8M | ||
| Q2 25 | $301.2M | $220.0M | ||
| Q1 25 | $359.7M | $279.4M | ||
| Q4 24 | $323.8M | $362.3M | ||
| Q3 24 | $397.5M | $359.8M | ||
| Q2 24 | $412.5M | $672.5M | ||
| Q1 24 | $356.2M | $305.5M |
| Q4 25 | $698.6M | $538.2M | ||
| Q3 25 | $702.3M | $503.6M | ||
| Q2 25 | $698.5M | $492.6M | ||
| Q1 25 | $767.9M | $484.5M | ||
| Q4 24 | $710.4M | $460.9M | ||
| Q3 24 | $773.5M | $530.3M | ||
| Q2 24 | $768.5M | $541.8M | ||
| Q1 24 | $680.0M | $539.5M |
| Q4 25 | $913.2M | $4.9B | ||
| Q3 25 | $904.9M | $5.0B | ||
| Q2 25 | $907.4M | $5.0B | ||
| Q1 25 | $966.7M | $4.9B | ||
| Q4 24 | $910.4M | $5.0B | ||
| Q3 24 | $991.1M | $5.0B | ||
| Q2 24 | $964.3M | $4.7B | ||
| Q1 24 | $869.8M | $5.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-18.8M |
| Free Cash FlowOCF − Capex | $-61.9M | $-23.6M |
| FCF MarginFCF / Revenue | -71.3% | -14.1% |
| Capex IntensityCapex / Revenue | 10.7% | 2.9% |
| Cash ConversionOCF / Net Profit | — | -0.59× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $-17.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $-18.8M | ||
| Q3 25 | $-78.7M | $34.3M | ||
| Q2 25 | $-67.4M | $25.2M | ||
| Q1 25 | $-103.7M | $-51.5M | ||
| Q4 24 | $-73.3M | $-247.1M | ||
| Q3 24 | $-59.0M | $-269.9M | ||
| Q2 24 | $-98.4M | $-8.7M | ||
| Q1 24 | $-122.3M | $24.1M |
| Q4 25 | $-61.9M | $-23.6M | ||
| Q3 25 | $-89.5M | $33.7M | ||
| Q2 25 | $-74.9M | $24.7M | ||
| Q1 25 | $-109.9M | $-52.7M | ||
| Q4 24 | $-77.5M | $-252.0M | ||
| Q3 24 | $-61.3M | $-270.8M | ||
| Q2 24 | $-98.9M | $-9.3M | ||
| Q1 24 | $-126.5M | $23.3M |
| Q4 25 | -71.3% | -14.1% | ||
| Q3 25 | -132.7% | 19.5% | ||
| Q2 25 | -124.9% | 14.1% | ||
| Q1 25 | -222.8% | -30.6% | ||
| Q4 24 | -105.1% | -198.9% | ||
| Q3 24 | -104.6% | -141.4% | ||
| Q2 24 | -317.9% | -4.9% | ||
| Q1 24 | -17685.3% | 11.6% |
| Q4 25 | 10.7% | 2.9% | ||
| Q3 25 | 16.1% | 0.4% | ||
| Q2 25 | 12.4% | 0.3% | ||
| Q1 25 | 12.6% | 0.7% | ||
| Q4 24 | 5.7% | 3.9% | ||
| Q3 24 | 3.9% | 0.4% | ||
| Q2 24 | 1.4% | 0.3% | ||
| Q1 24 | 583.4% | 0.4% |
| Q4 25 | — | -0.59× | ||
| Q3 25 | — | 33.61× | ||
| Q2 25 | — | 5.29× | ||
| Q1 25 | — | -5.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.14× | ||
| Q1 24 | — | 1.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
JRVR
| Excess And Surplus Lines | $156.7M | 93% |
| Specialty Admitted Insurance | $10.9M | 7% |
